Anti-Class II Antibody Production Prolongs Renal Allograft Survival

Lewis, Robert E.; Brackin, Martha N.; Cruse, Julius M.; Brackin, Bruce; Butkus, Debbie; Raju, Sree Bhushan; Crawford, Michael P.; Krueger, R.; Kirchner, Kent A.; Bower, John D.

doi:10.1159/000157157

Cited by 1 publication

(3 citation statements)

References 19 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By the introduction of the antigen-specific capture assay MAILA we could demonstrate that the formation of HLA-DR antibodies is significantly more frequent in rejecting patients than in patients without rejection episodes. This is in contrast to previous findings, assessing class II antibodies as enhancing or protective factors for the survival of renal allografts [3,6]. In patients with acute and chronic rejection, the prevalence of HLA-DR alloantibodies did not exceed 69.2% in the present study.…”

Section: Discussioncontrasting

confidence: 99%

“…Scornik et al [12] found donor-specific B-cell-reactive antibodies in posttransplant sera and nephrectomy eluates of 4 patients suffering from hyperacute or acute rejection. In contradiction, Lewis et al [6] observed that postoperative production of B-cell antibodies exerts a protective effect on renal allografts, whereas Ting and Morris [16] showed that graft outcome does not correlate with B-cell antibody production. Conversely, several studies have reported a significant correlation of anti-donor B-cell antibodies formed after transplantation in patients with chronic rejection [8,9,17].…”

Section: Introductionmentioning

confidence: 97%

“…Conversely, Taylor et al [4] described the case of a renal allograft that survived despite the presence of a donor-specific HLA-DQ IgG antibody causing a positive B-cell cross-match. Furthermore, it has been suggested that B-lymphocyte alloantibodies may exert an enhancing effect on renal graft survival [3,6]. Likewise, the impact of anti-HLA class II antibodies induced after transplantation remains unclear.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Association of HLA-DR Antibodies and Graft Rejection in Renal Transplantation: Posttransplant Analysis Using the Monoclonal Antibody-Specific Immobilization of Leukocyte Antigens Assay (MAILA)

Renner¹,

Santoso²,

Müller‐Steinhardt³

et al. 2004

Transfus Med Hemother

View full text Add to dashboard Cite

Background: The clinical impact of HLA-DR alloantibodies in renal transplantation is still controversial. This may be partly due to the lack of specificity and sensitivity of current detection methods, e.g. complement-dependent cytotoxicity test employing B lymphocytes as target antigens. Patients and Methods: In this study, we analyzed the incidence and specificity of HLA-DR antibodies after renal transplantation by use of the antigen-specific capture assay MAILA. 53 primary cadaver kidney recipients were recruited for a prospective study and were retrospectively assigned to the following groups: 20 patients with unsuspicious clinical course within the first 3 months after transplantation (control group), 20 patients undergoing histologically proven acute rejection within the first 3 months after transplantation, and 13 patients with chronic rejection 1 year or later after transplantation. 105 patients’ sera collected prospectively were analyzed by MAILA using 13 homozygous B-lymphoblastoid cell lines (B-LCL) carrying the common HLA-DR specificities. Results: In the control group, only 1 of 19 patients (5.3%) without acute rejection revealed HLA-DR antibodies after transplantation. In contrast, HLA-DR alloantibodies could be detected post transplant in 36.8% (7/19) and 69.2% (9/13) of patients with acute and chronic rejection, respectively. The frequency of HLA-DR antibodies present in both study groups was significantly higher in comparison to the control group. Of the 17 patients who received a graft across a donor recipient HLA-DR mismatch, 5 patients exhibited donor-specific alloantibodies. However, the majority of antibodies detected was not specific for mismatched HLA-DR alloantigens. Conclusion: HLA-DR antibodies were significantly associated with transplant rejection in first cadaver renal transplantation, especially in patients undergoing chronic rejection. Although donor specificity was not observed in the majority of patients, monitoring of HLA-DR antibodies might support diagnosis of graft rejection.

show abstract

Section: Discussioncontrasting

confidence: 99%